SynthesisClinical rheumatology2026
Hughes-Stovin syndrome (HSS) preliminary diagnostic criteria: a report by the HSS International Study Group (HSSISG).
Synthesis in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveHughes-Stovin syndrome (HSS) is a systemic vasculitis that remains an enigmatic and poorly understood clinical disorder. Despite this, no diagnostic criteria have been established since the disease was initially described in 1959. The objective of this report is to develop preliminary HSS diagnostic criteria proposed by the HSS International Study Group (HSSISG).
methodsThis international initiative included a systematic literature review of HSS case reports in a global endeavor. A systematic review of MEDLINE, EMBASE, and the Cochrane database identified 112 HSS patients. The selected reports were based on comprehensive case presentations, encompassing demographic characteristics, initial disease presentations, notable symptoms and signs, laboratory findings, radiological investigations, medical lines of treatment or interventional management received, and finally patients' outcomes. Diagnostic criteria were selected based on their clinical relevance, dominance, and consensus among the HSSISG members. Each criterion was discussed in detail to enhance comprehension and interpretation by physicians.
resultsFollowing consensus agreement, one mandatory entry criterion was selected which included pulmonary findings, along with one exclusion criterion regarding ocular aspects. Two major criteria were defined, vascular aspects and coagulation profile, and four minor criteria: mucocutaneous, central nervous system, cardiac, and inflammatory markers. The maximum achievable score is 30, with a suggested definitive diagnosis of HSS with scores 10 or higher, probable HSS with scores of 5-9, and possible HSS for scores 3-4. Scores < 3 are considered nondiagnostic.
conclusionPreliminary HSS diagnostic criteria were proposed after a comprehensive and critical literature review by the HSSISG to offer support for early diagnosis and optimal management.
Indexed as
Identifiers
41984348What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.